Exploring the mechanism of agonist efficacy: A relationship between efficacy and agonist dissociation rate at the muscarinic M₃ receptor

David A. Sykes, Mark R. Dowling & Steven J. Charlton

Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, UK
Running title:

Relating M₃ receptor agonist efficacy to dissociation rate

Corresponding author:

Steven J Charlton Novartis Institutes for Biomedical Sciences, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, UK, Tel: +44 1403 324203, Fax: +44 1403 323307, Email: steven.charlton@novartis.com

Number of text pages: 24
Number of tables: 2
Number of figures: 6
Number of references: 32
Number of words in Abstract: 245
Number of words in Introduction: 712
Number of words in Discussion: 1566

Abbreviations:

CHO, Chinese hamster ovary;

EDTA ethylenediaminetetra-acetic acid;

HBSS, Hanks Balanced Salt Solution;

MEM, minimal essential medium;

mACH, muscarinic acetylcholine;

[³H]-NMS, L-[N-methyl]-[³H]Scopolamine methyl chloride;

NSB, non-specific binding;

cTCM, cubic ternary complex model
Abstract

Although there are several empirical approaches that enable comparison of relative agonist efficacy, the molecular basis that underlies differences in the ability of G protein-coupled receptor agonists to elicit a response is still largely unexplained. Several models have been described that incorporate the kinetics of receptor-mediated initiation of the G protein cycle, but these have not directly addressed the influence of agonist binding kinetics. In order to test this we have investigated the relationship between the efficacy of seven M₃ muscarinic receptor agonists and their rate of dissociation ($k_{off}$) from the M₃ receptor. The association and dissociation rate constants of the agonists were determined using a $[^3H]$NMS competition binding assay in the presence of GTP. The agonists displayed a range of association and dissociation rates. Relative agonist efficacy was measured at two points after M₃ receptor activation; the stimulation of $[^35S]$GTPγS binding to Gα subunits and the subsequent increase in intracellular calcium levels. These experiments revealed a range of intrinsic efficacy, ranging from the low efficacy pilocarpine and oxotremorine to the high efficacy acetylcholine. There was no relationship between agonist efficacy and the equilibrium binding affinity of each agonist ($K_d$). When efficacy was compared to the dissociation rate constant, however, the two were highly correlated, suggesting a relationship between the duration of agonist binding at the receptor and the intrinsic efficacy. These data suggest that kinetic models incorporating the mean lifetime of specific complexes will be required to fully explain the nature of agonist efficacy.
Introduction

Efficacy is defined as the ability of a ligand to elicit a response upon binding to a receptor (Stephenson, 1956) and is arguably the most important parameter for optimization in novel agonist drugs. To date, efficacy has largely been treated as an empirical term and several approaches comparing equilibrium binding to functional potency have been described for its measurement (Black and Leff, 1983; Ehlert, 1985). Whilst providing a pragmatic approach to ranking ligands, these methods make no attempt to explain the molecular mechanism behind efficacy. One of the first attempts to provide a mechanistic explanation for agonist efficacy was by Paton (1961), termed “rate theory”. This model considers that excitation by a stimulant drug is proportional to the rate of drug-receptor combination, rather than to the proportion of receptors occupied by the drug. In this case, once the receptor has been activated and the signal transduced, it must be re-set by dissociation of the agonist before another activation event can be initiated by binding of another agonist molecule. Thus, a high efficacy ligand would dissociate rapidly from the receptor allowing another agonist to bind rapidly, while a low efficacy agonist would dissociated more slowly from the receptor, acting effectively as a competitive antagonist against other agonist molecules. This model was proposed after the observation that efficacy and off-set for a series of ligands at the guinea pig ileum were negatively correlated.

Since then, however, models have been developed that describe efficacy in terms of the ability to stabilize an active receptor conformation. Perhaps the most widely used is the two state model, originally described for activation of ion channels (del Castillo and Katz, 1957) but since adapted for use with G protein-coupled receptors (Karlin, 1967; Thron, 1973; Colquhoun, 1973; Leff, 1995). In this model, the efficacy of an agonist is dependent upon it’s affinity for $R^*$ (active conformation) over $R$ (inactive conformation).
Thus, an agonist that preferentially binds $R^*$ will drive the equilibrium between the two states toward the active conformation and will display high efficacy. If the binding affinity is higher for $R$ than $R^*$, an agonist will exhibit negative efficacy by driving the equilibrium towards the inaction state. A full spectrum of efficacy can be established between these two extremes, governed by the differential in affinity for the two receptor states. This model predicts that affinity and efficacy are inextricably linked (see Colquhoun, 1998), although unlike Paton’s rate theory, higher relative affinity at the active conformation would result in a higher efficacy agonist. This model has been extended to include the presence of G proteins in the extended ternary complex model (Samama et al., 1993) or the more thermodynamically complete cubic ternary complex model (Weiss et al., 1996). The assumption of equilibrium in these models is, however, a simplification, as the ternary complex is not stable and does not accumulate in the presence of agonist.

To address this, Waelbroeck et al. (1997) proposed a kinetic model where the receptor acts as an enzyme that catalyses GDP/GTP exchange on the G protein, and the agonist as an allosteric activator. In this model, once the GTP-bound G protein dissociates, the agonist-bound receptor is free to catalyse another reaction cycle. A similar kinetic approach has since been described for the cTCM, where the model was modified to include the breakdown of the ternary complex and recycling of G protein (e.g. Shea et al., 2000; Kinzer-Ursem and Linderman, 2007). Like the kinetic model of Waelbroeck and colleagues, providing the agonist remains bound to receptor it is able to catalyse multiple rounds of the G protein cycle.

According to these newer kinetic models, it may be hypothesised that the mean receptor residency time of a rapidly dissociating agonist may not be long enough to facilitate a full, productive turn of the cycle (thus showing low efficacy), while a
slowly dissociating agonist may catalyse several cycles before dissociating, thereby
displaying higher efficacy (refer to Scheme 1). To test this, we have determined the
dissociation rates of seven muscarinic M₃ receptor agonists and compared them to two
empirical measures of agonist efficacy, intrinsic activity (I.A.) and τ, from the
operational model of Black and Leff (1983), in an effort to test whether the observed
residency of an agonist at the receptor is directly linked to apparent efficacy.
Methods

Chemicals and reagents

$^{l}$-[N-methyl]-$^{3}$H]Scopolamine methyl chloride ($[^3$H]-NMS specific activity 80-90 Cimmol$^{-1}$) and Guanosine 5'-O-(3-Thiotriphosphate) ($[^35$S]-GTP$\gamma$S specific activity >1000 Cimmol$^{-1}$) and wheatgerm agglutinin SPA beads were obtained from Amersham Biosciences U.K. Ltd (GE Healthcare, Chalfont St Giles, U.K.). 96-deep well plates and 500 cm$^2$ cell culture plates were purchased from Fisher Scientific (Loughborough, U.K.). 96-well GF/B filter plates were purchased from Millipore (Watford, U.K.). HBSS, sodium bicarbonate, EDTA, sodium chloride, HEPES, DMSO, BSA, GTP, GDP, saponin, probenecid, acetylcholine chloride, carbachol chloride, methacholine chloride, bethanachol chloride, oxotremorine-M, oxotremorine sesquifumarate and pilocarpine hydrochloride were obtained from Sigma Chemical Co Ltd. (Poole U.K.). Brilliant black was obtained from ICN Biomedicals Inc (Ohio, USA). Pluronic acid, Fluo-4-AM and all cell culture reagents were purchased from GIBCO (Invitrogen, Paisley, U.K.).

Cell culture

Chinese hamster ovary (CHO) cells transfected with the cDNA encoding the human M$_3$ (CHO-M$_3$) muscarinic acetylcholine receptor was a kind gift from Professor S.R. Nahorski (Department of Cell Physiology and Pharmacology, University of Leicester, U.K.). CHO cells were grown in minimum essential medium (αMEM) supplemented with 10% new-born calf serum. Cells were maintained at 37°C in 5% CO$_2$/humidified air. Cells were routinely spit 1:10, using trypsin-EDTA to lift cells, and were not used in assays beyond passage 40.
Cell membrane preparation

CHO-cells expressing the M₃ mACh receptor were grown to 80-90 % confluency in 500 cm² cell-culture plates at 37 °C in 5 % CO₂. All subsequent steps were conducted at 4 °C to avoid receptor degradation. The cell-culture media was removed and ice cold HBS-EDTA (1x 10 mL; 10mM HEPES, 0.9 % w/v NaCl, 0.2 % w/v EDTA pH 7.4) was added to the cells which were then scrapped from the plates into a 50 mL Corning tube and subsequently centrifuged at 250 x g for 5 min to allow a pellet to form. The supernatant fraction was aspirated and 10 mL per 500 cm² tray of wash buffer (10 mM HEPES, 10 mM EDTA, pH 7.4) was added to the pellet. This was homogenized using an electrical homogenizer ‘Werker, ultra-turrax’ (position 6, 4 x 5 second bursts) and subsequently centrifuged at 48,000 x g at 4°C (Beckman Avanti J-251 Ultracentrifuge) for 30 min. The supernatant was discarded and the pellet re-homogenized and centrifuged as described above, in wash buffer. The final pellet was suspended in ice cold 10 mM HEPES, 0.1 mM EDTA, pH 7.4 at a concentration of 5-10 mg mL⁻¹. Protein concentration was determined by the Bio-Rad Protein Assay based on the method of Bradford (1976), using BSA as a standard and aliquots maintained at -80°C until required.

Common procedures applicable to all radioligand binding experiments

All radioligand experiments were conducted in 96 deep well plates, in assay binding buffer, HBSS pH 7.4 with GTP (100 μM), at 37 °C. In all cases non-specific binding (NSB) was determined in the presence of 1 μM atropine. After the indicated incubation period, bound and free [³H]-NMS were separated by rapid vacuum filtration using a FilterMate™ Cell Harvester (Perkin Elmer, Beaconsfield, U.K.) onto
96 well GF/B filter plates and rapidly washed three times with ice cold 20mM HEPES pH 7.4. After drying (>4 h), 40μL of Microscint™ 20 (Perkin Elmer, Beaconsfield, UK) was added to each well and radioactivity quantified using single photon counting on a TopCount™ microplate scintillation counter (Perkin Elmer, Beaconsfield, UK). Aliquots of [³H]-NMS were also quantified accurately to determine how much radioactivity was added to each well using liquid scintillation spectrometry on LS 6500 scintillation counter (Beckman Coulter, High Wycombe, U.K.). In all experiments, total binding never exceeded more than 10% of that added, limiting complications associated with depletion of the free radioligand concentration (Carter et al., 2007).

[³H]-NMS saturation binding

Binding was performed with a range of concentrations of [³H]-NMS (~ 0.004 – 8 nM) to construct saturation binding curves, as described by Dowling and Charlton (2006). CHO-M₃ cell membranes (10 μg well⁻¹) were incubated in 96-deep well plates at 37°C in assay binding buffer with gentle agitation for 3 h, to ensure equilibrium was reached. Owing to the low concentrations of [³H]-NMS employed, the assay volume was increased to 1.5 mL to avoid significant ligand depletion.

Determination of agonist Kᵢ

To obtain affinity estimates of unlabelled agonists, [³H]-NMS competition experiments were performed at equilibrium. [³H]-NMS was used at a concentration of approximately 350 pM (~ 40,000 c.p.m. in a volume of 1.5 mL) such that the total binding never exceeded more than 10% of that added. [³H]-NMS was incubated in the
presence of the indicated concentration of unlabelled agonist and CHO-cell membranes (10 μg well⁻¹) at 37 °C with agitation for 3 h.

**Determination of the association rate \(k_{on}\) & dissociation rate \(k_{off}\) of \[^3H\]-NMS**

To determine the \(k_{on}\), the \(k_{off}\) was calculated at three different concentrations of \[^3H\]-NMS (approximately 222, 666 & 2000 pM; exact concentrations were calculated in each experiment using liquid scintillation counting). The experiment was initiated \((t=0)\) by addition of CHO-M₃ cell membranes (10 μg well⁻¹) to \[^3H\]-NMS in assay binding buffer (final assay volume 500 μL) and incubated with gentle agitation. Free \[^3H\]-NMS was separated at multiple time points to construct association kinetic curves. Care was taken to ensure saturation for each experiment was reached before the experiment was terminated. After incubation, bound was separated from free by rapid filtration, plates were left to dry and radioactivity quantified (as previously described). The kinetic rate constants for \[^3H\]-NMS were calculated as described below in the data analysis section.

**Competition kinetics**

The kinetic parameters of unlabelled agonists were assessed using a competition kinetic binding assay as described by Dowling and Charlton (2006). Approximately 2 nM \[^3H\]-NMS (a concentration which avoids ligand depletion in this assay volume) was added simultaneously with the unlabelled compound to CHO-M₃ membranes (10 μg well⁻¹) in 500 μL assay buffer. The degree of \[^3H\]-NMS bound to the receptor was assessed at multiple time points by filtration harvesting and liquid scintillation counting, as described previously. Non-specific binding was determined as the amount of radioligand bound to the filters and membrane in the presence of atropine.
(1μM) and was subtracted from each time point, meaning that t=0 was always equal to zero. Each time point was conducted on the same 96-deep well plate incubated at 37°C with constant agitation. Reactions were considered stopped once the membranes reached the filter and the first wash was applied within 1 s. Three different concentrations of unlabelled competitor were tested to ensure the rate parameters calculated were independent of ligand concentration. All compounds were tested at 10, 3, and 1-fold their respective $K_i$ and data were globally fitted using equation 2 to simultaneously calculate $k_{on}$ and $k_{off}$.

**Measurement of changes in cytoplasmic [Ca$^{2+}$] using a fluorometric imaging plate reader**

CHO-M3 cells were seeded into 96-well black plates (Costar) at 50,000 cells per well in 100 μL tissue culture medium, supplemented as above, and incubated at 37 °C, 5 % CO₂ for approximately 24 h. On the day of the experiment, the cells were loaded in HBSS w/o phenol red containing 0.1 % (w/v) BSA, HEPES (20 mM), Fluo-4-AM (2 μM, 50 μg Fluo-4-AM dissolved in 44 μL DMSO : Pluronic acid (1:1)), probenecid (250 μM) and brilliant black (100 μM), and incubated at 37 °C, 5 % CO₂ for 30 min. Agonist-induced changes in Ca$^{2+}$ concentration were monitored using fluorometric imaging plate reader (FLIPR; Molecular Devices, UK). The laser intensity on the FLIPR was set between 0.4 - 0.5 W, a level sufficient to obtain basal fluorescence of ~10,000 U. Basal fluorescence was monitored for 10 s prior to addition of 50 μL muscarinic agonist at a speed of 50 μL s$^{-1}$ and the fluorescence change monitored for 5 min. Responses to agonist were expressed as change in fluorescence from baseline to peak. The maximum fluorescence was taken as the highest point of the initial peak.
following agonist addition. The minimum fluorescence was taken as the background fluorescence prior to agonist addition.

[^35S]-GTPγS binding assay

The[^35S]GTPγS binding assays were performed in white 96-well optiplates in a final volume of 250 µL as follows. In brief, the frozen cell membranes were thawed and resuspended in GTPγS binding buffer (HBSS containing 20 mM HEPES, 10 µg/mL saponin, 0.1 % (w/v) BSA pH 7.4). Membranes (30 µg/well), GDP (1 µM), SPA beads (1 mg/well),[^35S]-GTPγS (300 pM) and the muscarinic M₃ agonists at a range of concentrations were added to the plates. Plates were incubated for a further 1h at 30°C with shaking prior to centrifugation at 3000 rpm (Jouan B4i) for 3 minutes and then read on the TopCount™ (30 seconds per well).

Data analysis

As the amount of radioactivity varied slightly for each experiment (< 5%), data are shown graphically as the mean ± range for individual representative experiments, whereas all values reported in the text and tables are mean ± s.e.mean for the indicated number of experiments. All experiments were analyzed by either linear or non-regression using Prism 4.0 (GraphPad Software, San Diego, U.S.A.). Competition displacement binding data were fitted to sigmoidal (variable slope) curves using a “four parameter logistic equation”:

\[ Y = \text{Bottom} + (\text{Top} - \text{Bottom}) / \left( 1 + 10^{(\log EC_{50} - X)/\text{Hillockefficient}} \right) \] (1)
IC₅₀ values obtained from the inhibition curves were converted to Kᵢ values using the method of Cheng and Prusoff (1973).

[³H]-NMS association data were globally fitted to the following equation to determine a single best fit estimate for $k_{on}$ and $k_{off}$:

$$K_{ob} = [\text{radioligand}] * k_{on} + k_{off} \quad (2)$$

Association and dissociation rates for unlabeled agonists were calculated by simultaneously fitting the data for each competitor concentration to equation 3.

$$S = \sqrt{((K_A - K_B) + 2 + 4 * k_1 * k_3 * L * I * 1e^{-18})}$$

$$K_F = 0.5 * (K_A + K_B + S)$$

$$K_S = 0.5 * (K_A + K_B - S)$$

$$\text{DIFF} = K_F - K_S$$

$$Q = \frac{B_{\text{max}} * K_1 * L * 1e^{-9}}{\text{DIFF}}$$

$$Y = Q * \left( \frac{k_4 * \text{DIFF}}{K_F * K_S} + \frac{k_4 - K_F e^{(-K_x * X)}}{K_F} - \frac{k_4 - K_S e^{(-K_x * X)}}{K_S} \right) \quad (3)$$

where X = Time (min), Y = Specific binding (c.p.m.), $K_1 = k_{on}$ [³H]-NMS, $K_2 = k_{off}$ [³H]-NMS, L = Concentration of [³H]-NMS used (nM), I = Concentration of unlabeled agonist (nM). Fixing the above parameters allowed the following to be simultaneously calculated: $B_{\text{max}}$ = Total binding (c.p.m), $k_3$ = Association rate of
unlabeled ligand (M$^{-1}$ min$^{-1}$) or $k_{on}$, $k_4$ = Dissociation rate of unlabeled ligand (min$^{-1}$) or $k_{off}$.

To evaluate the relative efficacy of agonists that produced the same maximal response in the calcium assay, data were fitted to the operational model of Black and Leff (1983). This model describes the correlation between a biological effect $E$ and agonist concentration $[A]$ as a function of three parameters: $E_m$, $K_A$, and $\tau$:

$$E = \frac{E_m * \tau * [A]}{K_A + [A] + \tau * [A]}$$

(4)

where $E_m$, or the operational maximum, represents the maximum possible effect in the tissue, $K_A$ is the dissociation constant of the agonist and $\tau$ is the operational efficacy or the transducer ratio. When equation 4 was applied to data, $[A]$ was varied according to experimental design, $K_A$ was fixed to the value obtained in competition binding assays (run in identical conditions to the functional experiments), $E_m$ was globally fitted across all data sets, leaving $\tau$ as the only term fitted individually for each agonist.
Results

Characterisation of M<sub>3</sub> receptor-expressing CHO cell line.

Specific [<sup>3</sup>H]-NMS binding to muscarinic receptors in CHO-M<sub>3</sub> membranes was saturable and best described by the interaction of the radioligand with a single population of high affinity binding sites. The expression level of the M<sub>3</sub> CHO-cell line was estimated from the B<sub>max</sub> in [<sup>3</sup>H]-NMS saturation binding as 3.0 ± 0.4 pmol mg<sup>-1</sup> (n=4). From these studies the equilibrium dissociation constant (K<sub>d</sub>) of [<sup>3</sup>H]-NMS was determined to be 289 ± 13 pM (n=4).

[<sup>3</sup>H]-NMS competition binding studies

The CHO-M<sub>3</sub> receptor binding profile of the seven muscarinic agonists was determined in buffer containing GTP (100 μM). GTP was included to ensure that agonist binding only occurred to the uncoupled form of the M<sub>3</sub> receptor. All seven agonists produced concentration-dependent inhibition of specific [<sup>3</sup>H]-NMS binding binding. Examples of competition curve data are shown in Figure 1 and pK<sub>i</sub> values were determined as shown in Table 1. Slope parameter estimates for all agonists tested were not different from unity suggesting that binding occurs to a single population of receptor.

Characterisation of [<sup>3</sup>H]-NMS kinetic parameters.

A family of association kinetic curves were constructed using a range of [<sup>3</sup>H]-NMS concentrations. Each association curve was monitored until equilibrium was achieved (Figure 2). The data were globally fitted to derive a single best fit estimate for the k<sub>on</sub>
and $k_{\text{off}}$ of $[^{3}\text{H}]-\text{NMS}$. Mean values obtained for the on- and off-rates were $9.26 \pm 0.69 \times 10^{8} \text{M}^{-1}\text{min}^{-1}$ and $0.30 \pm 0.05 \text{min}^{-1}$, respectively. The kinetically derived $K_{\text{d}}$ ($k_{\text{off}}/k_{\text{on}}$) calculated from the mean values for the individual experiments ($341 \pm 72 \text{pM}$) was in good agreement with the value obtained from $[^{3}\text{H}]-\text{NMS}$ saturation experiments $289 \pm 13 \text{pM}$.

**Competition kinetic binding**

This method models the binding between two ligands, one labeled and one unlabelled, competing for the same receptor site. Representative curves for acetylcholine and pilocarpine are shown in Figure 3A and 3B, respectively. The pattern of $[^{3}\text{H}]-\text{NMS}$ binding over time was dependent upon the off-rate of the competing agonist. $[^{3}\text{H}]-\text{NMS}$ association in the presence of more slowly equilibrating competitors (slow off-rate) was two-phase. The initial, rapid phase was equivalent to the rate of association of radioligand alone and represents binding to free receptors. The second phase represents equilibration of the two ligands with the receptor and was significantly slower. In the presence of more rapidly equilibrating agonists the first phase of $[^{3}\text{H}]-\text{NMS}$ binding was much less apparent because the majority of free receptors (at $t = 0$) were occupied first by the competitor. Progression curves for $[^{3}\text{H}]-\text{NMS}$ alone and in the presence of three different concentrations of competitor were globally fitted to equation 2, enabling the calculation of both $k_{\text{on}}$ ($k_{3}$) and $k_{\text{off}}$ ($k_{4}$) for each of the agonists, as reported in Table 1. As the $k_{\text{off}}$ values were similar across the cohort we tested whether the data were sufficient to discriminate between the agonists. The quality of fit was worse when the $k_{\text{off}}$ was fixed to any value outside that predicted by simultaneous fitting. There was a much larger difference in $k_{\text{on}}$ values between the agonists. Interestingly these correlated well with the $K_{\text{d}}$ ($r^{2} = 0.92$, $p < 0.001$ for $\log k_{\text{on}}$
versus p\(K_d\), suggesting that it is the on-rate that governs the equilibrium affinity of these agonists. To validate the rate constants, the kinetically derived \(K_d\) values \((k_{off}/k_{on})\) were compared to the affinity constant \((K_i)\) obtained from equilibrium competition binding experiments (Figure 4). Although there was a very good correlation \((r^2 = 0.99)\) between these two values, there was a small (approximately 2-fold) but consistent difference for all the agonists.

**Measurement \([^{35}S]\)-GTP\(_\gamma S\) binding activity**

Each ligand stimulated the incorporation of \([^{35}S]\)-GTP\(_\gamma S\) to the CHO-M\(_3\) membranes, displaying a range of potency and intrinsic activity (Figure 5a, Table 2). When the data were simultaneously fitted to the Operational Model, \(\tau\) values were very low, suggesting there was little, if any receptor reserve at this early step in the transduction pathway.

**Measurement of changes in cytoplasmic \([Ca^{2+}]\)**

All seven of the muscarinic agonists tested stimulated an increased intracellular calcium concentration in CHO-M\(_3\) cells (Figure 5b). The maximal response to these ligands did not differ significantly from each other \((P < 0.05)\) despite the fact that some of these ligands were partial agonists in the GTP\(_\gamma S\) assay. This is likely due to the greater degree of amplification associated with calcium signaling. As relative efficacy could not be determined in this system by comparing maximal agonist responses, the data were fitted to an operational model that compares binding affinity to functional potency to calculate \(\tau\), a value that can be used to compare relative efficacies of agonists when tested in the same system (Black and Leff, 1983). A range
of τ values were obtained that broadly agreed with the rank order of intrinsic activity from the [³⁵S]-GTPγS binding assay (Table 2).

**Relationship between agonist efficacy & k_{off}**

There was no relationship between the affinity (K_d) of the seven agonists tested here and their relative efficacy determined either in the calcium assay (r² = 0.05, p = 0.63) or [³⁵S]-GTPγS (r² = 0.26, p = 0.24) (Figure 6A and 6C, respectively). Similarly, there was no relationship between k_{on} and efficacy (r² = 0.23, p = 0.28 and r² = 0.32, p = 0.19 from Ca^{2+} and GTPγS data, respectively) (correlation not shown). However, when the efficacy of each agonist was compared to its dissociation rate constant (k_{off}), a highly significant correlation was obtained, with the highest efficacy ligands having the slowest dissociation rates. This correlation was observed when k_{off} was compared to either τ from the calcium assay (r² = 0.98, p < 0.0001) or intrinsic activity (I.A.) from the GTPγS data (r² = 0.95, p = 0.0002), suggesting the dissociation rate for these muscarinic agonists plays an important role in defining efficacy at the M₁ receptor (Figure 6B and 6D).
Discussion

The aim of this study was to investigate whether the observed rate of agonist dissociation is related to observed efficacy, such that the receptor residency time of a rapidly dissociating agonist is not always long enough to facilitate a full, productive G protein activation event (thus showing low efficacy), while a slowly dissociating agonist may catalyse several G protein activation cycles before dissociating, thereby displaying higher efficacy.

In order to assess relative agonist efficacy, we measured M₃-mediated activation at two different points, direct activation of Gα subunits using GTPγS binding and the subsequent release of intracellular calcium. The agonists displayed different maximal responses in the GTPγS assay, but were all maximally effective in the calcium experiments. In order to determine relative efficacy from the calcium data, we fitted the data to the operational model of Black and Leff (1983). The values obtained using this method were in broad agreement with intrinsic activity measurements from the GTPγS assay.

To determine the dissociation kinetics of the seven agonists we employed a competition kinetic method using a radiolabelled antagonist, [³H]-NMS (Dowling and Charlton, 2006). The agonists displayed a range of dissociation rate constants, from 5.6 min⁻¹ for acetylcholine to 17.6 min⁻¹ for oxotremorine. The off-rate of acetylcholine is moderately faster than that previously described by Kellar et al. (1985) using [³H]-acetylcholine (1.04 min⁻¹), but this was at performed at 25 °C in cerebral cortex and likely represents a mixture or rates from a variety of muscarinic receptor subtypes. The association rate constants of these agonists were significantly slower than those previously reported for antagonists at the M₃ receptor (Dowling and
Charlton, 2006). This is contrary to the generally assumed situation that equilibrium affinity is governed predominantly by off-rate and that on-rate is effectively diffusion-limited. It is, however, consistent with previous attempts to measure agonist kinetics at muscarinic receptors using competition binding (Schreiber et al., 1985). Although the rate constants described by Schreiber and colleagues can not be directly compared to those obtained in the current study as binding was performed in brain tissue where multiple muscarinic receptor subtypes exist, the authors demonstrated that at the low affinity receptor site, the association kinetics were 2-5 orders of magnitude lower for agonists when compared to antagonists. Sklar and colleagues (1985) made similar observations, where formyl peptide agonist affinity was largely governed by changes in on-rate rather than off-rate. These reports are consistent with our current observation that it is predominantly the $k_{on}$ that defines the equilibrium affinity of muscarinic agonists.

We have measured the kinetic rate constants in the presence of GTP to remove any pre-existing high affinity guanine nucleotide-free (ARG) complexes that may have complicated the analysis (e.g. Cohen et al., 1996). It is important to note, however, that we can not definitively ascribe our measured rate constants to a single receptor-G protein complex. Indeed, the two-state model would predict that they comprise a mixture of microscopic rate constants and that these are directly influenced by the efficacy of the agonist (see Colquhoun, 1998). For example, a high efficacy ligand may more effectively stabilize the activated, high affinity $AR^\ast G_{(GTP)}$ complex, thereby displaying a slower dissociation rate than an agonist that is unable to promote isomerisation to the high affinity state. Despite this, the observed, macroscopic dissociation rate constants are still useful descriptors of the mean residency time at the receptor, even though they likely represent a mixture of microscopic rate constants.
The data presented in this report are not consistent with the notion that macroscopic equilibrium affinity is correlated to observed efficacy. Rather, we have demonstrated a clear relationship between the efficacy of these muscarinic agonists with the rate of dissociation from the M₃ receptor. Can this be reconciled with what we understand about the transduction of receptor-signals and the G protein activation cycle? We have shown that the half-life of the agonists tested ranges from between 7.8 seconds for acetylcholine to 2.6 seconds with oxotremorine. If the efficacy of oxotremorine is limited by its duration at the receptor, the activation interval would need to be in the range of 2.6 seconds or below so that oxotremorine is not always able to promote a productive turn of the G protein cycle. Whereas the conformational change in receptor and resultant receptor-G protein interaction proceeds very rapidly after agonist binding, in the range of 30-50 ms (reviewed by Lohse et al., 2008), the next step in the activation cycle, GDP release from the alpha subunit, is slow and represents the rate-limiting step in the G protein cycle. Biddlecome and colleagues (1996) measured the rate of GDP dissociation from Gα₉ after carbachol-induced activation by the M₁ muscarinic receptor and found that at a saturating concentration on carbachol, GDP dissociation from Gα₉ was biphasic with constants of 20 min⁻¹ and 1.4 min⁻¹. Due to differences in experimental protocol it is not possible to directly compare these time constants with those described in the current study, but it suggests that the rate limiting step in the cycle may occur at a similar rate to the mean residency time of oxotremorine at the M₃ receptor (2.6 sec). It is therefore possible that not all receptor binding events will last long enough to promote dissociation of GDP and will not therefore activate a productive turn of the G protein cycle.
Several other groups have made similar observations, albeit comparing just two ligands. Sklar et al. (1985) found that at the formyl peptide receptor, the full agonist FNLPNTL-FL dissociated with a rate constant of 0.35 min\(^{-1}\), whereas the dissociation rate of the partial agonist FMP was much faster at 5.1 min\(^{-1}\). A similar relationship was reported for the \(\alpha_2\)-adrenoceptor agonists UK14,304 and clonidine (Paris et al., 1989). Dissociation experiments using the radiolabelled forms of the agonist showed two rate constants, but in each case the off-rates of the full agonist UK14,304 were at least 10-fold slower than that of the partial agonist clonidine (0.08 min\(^{-1}\) and 1.0 min\(^{-1}\) for the fastest phase, respectively). These experiments were performed at 25 °C, but more recently, Hoeren and colleagues (2008) have repeated these findings at 37 °C, where it was found that the median binding of duration of UK14,304 was around 3-fold longer than that of clonidine (79.8 s and 27.6 s, respectively). A key issue with these examples is that in each case only two ligands were examined. In this present study we chose a larger cohort of agonists to represent a broader range of intrinsic efficacy. Interestingly, however, rather than an even distribution of efficacy and dissociation rates, the seven ligands examined here tended to form two separate groups of high efficacy ligands with slow off-rates and lower efficacy ligands with more rapid dissociation kinetics. This could be a chance occurrence that reflects the need to test much larger agonist collections. Alternatively, it could be a nature of the conformational change induced by the agonists, whereby a longer residency provides sufficient time for the receptor to isomerise into the high affinity state, effectively locking the agonist into the receptor. There may even be a threshold duration at the receptor after which the receptor can isomerise. Hence it can not be concluded that receptor residency drives efficacy or vice versa, but rather that both elements are inextricably linked.
It is clear that this correlation of long receptor residency with higher efficacy is in
direct contrast to Paton’s “rate theory”, (Paton, 1961), where he argued that high
efficacy ligands dissociate quickly from the receptor, permitting a more rapid
breakdown of the ternary complex so that the system would reset faster allowing a
second activation event to occur. There is evidence now, however, that the G protein
does not necessarily dissociate from receptor, meaning that the agonist does not have
to dissociate from the receptor for the G protein to dissociate (reviewed by Lambert,
2008). This implies that the same agonist-receptor-G protein complex could cycle
several times before dissociation of the agonist, the rate of which would depend upon
GDP dissociation to form the high-affinity ARG complex (see Scheme 1).
The present study has focused on G protein-mediated responses, but there are a
growing number of examples of alternative GPCR signaling pathways, e.g β-arrestin-
mediated events (DeFea, 2008). It is interesting to consider whether efficacy at these
other pathways might also be defined, in part, by the residency time of the agonist at
the receptor. It has been shown that agonist withdrawal leads to swift dissociation of
the receptor-β-arrestin2 complex, demonstrating that interaction of β-arrestin2 with
the β2 adrenoceptor is highly dependent upon coincident agonist binding (Krasel et al.,
2005). It is therefore plausible that an agonist that dissociates slowly from this
complex may be more likely to initiate a downstream signal. There are other
examples, however, where the efficacy measured at two different pathways is not
correlated (e.g. Galandrin and Bouvier, 2006), suggesting that the agonists stabilize
discrete active conformations that may have different efficiencies across multiple
pathways (Kenakin, 2007). Investigating the relationship between agonist off-rate and
efficacy at these alternative, non-G protein-mediated pathways will be an interesting area for future investigations.

In summary, we have shown that agonist efficacy is positively correlated to duration at the receptor. This suggests that equilibrium models alone are not sufficient to describe a dynamic signaling system and that kinetic models incorporating duration of agonist binding alongside the rate of effector activation will be required to fully explain the nature of efficacy at G protein-coupled receptors.
References


Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. *Biochem Pharmacol* **22**:3099-3108.


MOL #54452


Legends

Scheme 1. Graphical representation of agonist-mediated G protein activation.

Figure 1. Competition between [3H]-NMS and increasing concentrations of muscarinic agonists for muscarinic M3 receptors in CHO cell membranes. Experiments were conducted in HBSS at 37°C. As the total binding varied data are shown as mean ± range from a representative of ≥4 experiments performed in duplicate and plotted as percent specific bound.

Figure 2 Characterisation of the kinetic parameters of [3H]-NMS. The $k_{on}$ and $k_{off}$ were determined by incubation of CHO-M3 cell membranes (10μg well$^{-1}$) with indicated concentrations of [3H]-NMS for various time points. Experiments were conducted in HBSS at 37°C. Data were globally fitted to the association kinetic model to derive a single best fit estimate for the $k_{on}$ and $k_{off}$. Data are shown as mean ± range from a representative of ≥4 experiments performed in duplicate and plotted as specific bound.

Figure 3. Example [3H]-NMS competition kinetic curves in the presence of (A) acetylcholine or (B) pilocarpine. CHO-M3 membranes were incubated with ~2nM [3H]-NMS and either 0, 1, 3, & 10-fold $K_i$ of competitor. Plates were incubated at 37°C with constant shaking for the indicated time points and NSB levels determined in the presence of atropine (1μM). Data were globally fitted to the equations described in the methods to calculate $k_{on}$ and $k_{off}$ values for the unlabelled agonists. The whole data set are summarized in Table 1. As the total binding varied from experiment to
experiment, data are presented as mean ± range from a representative of ≥4 experiments performed in duplicate and plotted as specific bound.

Figure 4. Correlation between pKᵢ and kinetically derived pKₐ for the seven test agonists. pKᵢ values were taken from [³H]-NMS competition binding experiments at equilibrium, see Figure 1. The values comprising the kinetically derived Kₐ (k₉/k₉ₐ) were taken from the experiments in Figure 3. Data shown as mean s.e.m. (n= ≥4).

Figure 5. Concentration-response curves of M₃ muscarinic agonists, measuring GTPγS binding to CHO-M₃ membranes (A) and agonist-induced Ca²⁺ mobilisation from CHO-M₃ cells, fitted to the Operational Model to derive τ and (B). For GTPγS binding data are mean ± s.e.m. from ≥4 separate experiments. For Ca²⁺ mobilisation since measured florescence varied from experiment to experiment, data are presented as mean ± range from a representative of ≥6 experiments, each performed in duplicate.

Figure 6. Correlation of relative agonist efficacy with pKₐ and log k₉. Logτ, calculated by fitting the Operational Model to calcium mobilisation data (in Figure 5B), was plotted against pKₐ (A) and log k₉ (B). Intrinsic activity, measured from GTPγS binding as the top of the concentration-response curves (in Figure 5A), was plotted against pKₐ (C) and log k₉ (D). All data used in these plots are detailed in Tables 1 and 2. Data are expressed as mean ± s.e.m. from ≥4 separate experiments.
**Tables**

**Table 1.** Binding parameters for agonists at the human M₃ muscarinic receptor derived from equilibrium and kinetic competition experiments with [³H]-NMS. Data are mean ± s.e.m. from 4-6 separate experiments.

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Kinetic</th>
<th>Equilibrium</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$k_{on}$</td>
<td>$k_{off}$</td>
</tr>
<tr>
<td></td>
<td>(M⁻¹ min⁻¹)</td>
<td>(min⁻¹)</td>
</tr>
<tr>
<td>Acetylcholine</td>
<td>1.82 ± 0.32 x 10⁵</td>
<td>5.6 ± 0.6</td>
</tr>
<tr>
<td>Carbachol</td>
<td>0.58 ± 0.01 x 10⁵</td>
<td>8.8 ± 1.1</td>
</tr>
<tr>
<td>Methacholine</td>
<td>1.20 ± 0.07 x 10⁵</td>
<td>7.9 ± 0.8</td>
</tr>
<tr>
<td>Oxotremorine M</td>
<td>1.43 ± 0.25 x 10⁵</td>
<td>6.9 ± 1.1</td>
</tr>
<tr>
<td>Bethanachol</td>
<td>0.48 ± 0.07 x 10⁵</td>
<td>13.3 ± 2.2</td>
</tr>
<tr>
<td>Oxotremorine</td>
<td>5.12 ± 1.56 x 10⁶</td>
<td>17.6 ± 2.6</td>
</tr>
<tr>
<td>Pilocarpine</td>
<td>4.47 ± 0.53 x 10⁵</td>
<td>15.3 ± 2.3</td>
</tr>
</tbody>
</table>
Table 2. Relative agonist efficacy derived from both $[^{35}\text{S}]$GTP$\gamma$S binding and calcium release experiments. Data are mean ± s.e.m. from 4-6 separate experiments.

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Calcium release (pEC$_{50}$)</th>
<th>I.A. (relative to MCh response)</th>
<th>Log $\tau$ (Ca$^{2+}$)</th>
<th>$[^{35}\text{S}]$GTP$\gamma$S binding (pEC$_{50}$)</th>
<th>I.A. (relative to MCh response)</th>
<th>Log $\tau$ (GTP$\gamma$S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetylcholine</td>
<td>9.33 ± 0.08</td>
<td>1.02 ± 0.04</td>
<td>4.45 ± 0.06</td>
<td>4.99 ± 0.11</td>
<td>1.36 ± 0.05</td>
<td>0.06 ± 0.17</td>
</tr>
<tr>
<td>Carbachol</td>
<td>7.98 ± 0.13</td>
<td>1.09 ± 0.05</td>
<td>3.95 ± 0.12</td>
<td>4.64 ± 0.16</td>
<td>1.16 ± 0.05</td>
<td>0.01 ± 0.16</td>
</tr>
<tr>
<td>Methacholine</td>
<td>8.52 ± 0.05</td>
<td>1.00</td>
<td>3.97 ± 0.05</td>
<td>5.01 ± 0.03</td>
<td>1.00</td>
<td>-0.11 ± 0.15</td>
</tr>
<tr>
<td>Oxotremorine M</td>
<td>8.76 ± 0.09</td>
<td>0.99 ± 0.04</td>
<td>4.14 ± 0.09</td>
<td>5.59 ± 0.10</td>
<td>1.44 ± 0.02</td>
<td>0.19 ± 0.19</td>
</tr>
<tr>
<td>Bethanachol</td>
<td>6.77 ± 0.09</td>
<td>0.96 ± 0.05</td>
<td>3.03 ± 0.09</td>
<td>4.62 ± 0.15</td>
<td>0.51 ± 0.04</td>
<td>-0.50 ± 0.10</td>
</tr>
<tr>
<td>Oxotremorine</td>
<td>8.47 ± 0.10</td>
<td>1.00 ± 0.03</td>
<td>2.89 ± 0.10</td>
<td>5.59 ± 0.23</td>
<td>0.35 ± 0.02</td>
<td>-0.82 ± 0.15</td>
</tr>
<tr>
<td>Pilocarpine</td>
<td>7.72 ± 0.08</td>
<td>0.94 ± 0.03</td>
<td>2.88 ± 0.09</td>
<td>5.05 ± 0.14</td>
<td>0.35 ± 0.04</td>
<td>-0.79 ± 0.12</td>
</tr>
</tbody>
</table>
Scheme 1

A + RG_{GDP} 

\[
\begin{align*}
A + R & \leftrightarrow AR \\
G_{GD} & \rightarrow ARG_{GD} \\
G_{GT} & \leftarrow ARG_{GT} \\
P & \leftrightarrow P \\
GDP & \rightarrow GDP \\
GTP & \leftarrow GTP \\
Pi & \leftrightarrow Pi
\end{align*}
\]
Figure 1

% specific bound $[^3H] \cdot \text{NMS}$

[Agonist] : $\log M$

- acetylcholine
- carbachol
- methacholine
- oxotremorine-M
- bethanachol
- oxotremorine
- pilocarpine
Figure 2

[³H]-NMS specific bound (c.p.m.) vs Time (min)

[³H]-NMS : nM
- 0.24
- 0.76
- 2.12
Figure 5

A

% of methacholine response

[agonist] (logM)

B

fluorescence units (max-baseline)

[agonist] (logM)

- acetylcholine
- carbachol
- methacholine
- oxotremorine-M
- bethanachol
- oxotremorine
- pilocarpine